Clinical Updates | Conference Update Resource List

Last Updated on May 17, 2020 by HepFree NYC
Tags: HepCX NewsA network building capacity to prevent, manage and treat hepatitis B and C in NYC

Last Updated on May 17, 2020 by HepFree NYC
Tags: HepCX NewsGovernor Andrew M. Cuomo today signed into law a bill that increases access to hepatitis C, or HCV, tests by allowing physicians and nurse practitioners to authorize registered nurses, when appropriate, to administer the test to a patient without the need for a patient-specific o...
Olysio has been approved by the FDA, in combination with Sovaldi, for the treatment of Hepatitis C. It is substantially more expensive than Harvoni; although it depends on treatment time, a 12-week Harvoni treatment costs $94,500, compared to the Olysio-Sovaldi 12-week tag of $1...
The President's FY2014 budget has not yet been released. We need your help in raising awareness among Members of Congress about the viral hepatitis epidemics and asking their support for increased funding for viral hepatitis activities at the federal level. Viral hepatitis adv...
This Plan updates the Center’s current strategic plan and serves as a blueprint for achieving our vision of a future free of HIV, viral hepatitis, STDs, and TB.
The Obama Administration has released a letter, through the Centers for Medicare and Medicaid Services (CMS), calling on states to stop imposing conditions for coverage of HCV drugs that may unreasonably restrict access to these drugs.
Over 500 Hep Free NYC LGBTQ Resource Cards were passed out during LGBTQ Pride.
An American Immigrant women’s study. You are invited to join a women’s health and safety study available in English, Spanish, French, Hmong, Arabic, Swahili and Somali. You can receive up to $40 for each completed survey; $115 for the whole year. See here for more in...
Addressing the unique needs and wants of the healthcare community is an important task. By participating in paid surveys, patients voice their opinions and concerns regarding the future of healthcare.